Science and Research

The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease

BACKGROUND: Granulomatous and lymphocytic interstitial lung disease (gl-ILD) is a major cause of morbidity and mortality among patients with common variable immunodeficiency. Corticosteroids are recommended as first-line treatment for gl-ILD, but evidence for their efficacy is lacking. OBJECTIVE: We analyzed the effect of high-dose corticosteroids (≥0.3mg/kg prednisone equivalent) on gl-ILD, measured by high-resolution computed tomography (HRCT) scans, pulmonary function test (PFT) results. METHODS: Patients who had received high-dose corticosteroids but no other immunosuppressive therapy at the time (n=56) and who underwent repeated HRCT scanning or PFT during the retrospective and/or prospective phase of the STILPAD study (n=39) were included in the analysis. Patients without any immunosuppressive treatment were selected as controls (n=23). HRCT scans were blinded, randomized and scored using the Hartman score. Differences between the baseline and follow up HRCT scans and PFT were analyzed. RESULTS: Treatment with high-dose corticosteroids significantly improved HRCT scores and forced vital capacity. Carbon monoxide diffusion capacity significantly improved in both groups. 13/18 patients, for whom extended follow-up data was available, achieved a long-term, maintenance therapy independent remission. All patients with relapse were re-treated with corticosteroids, but only 1/5 responded. Two opportunistic infections were found in the corticosteroid treatment group, while overall infection rate was similar between cohorts. CONCLUSION: Induction therapy with high-dose corticosteroids improved HRCT scans and PFT results of patients with gl-ILD and achieved long-term remission in 42% of patients. It was not associated with major side-effects. Low dose maintenance therapy provided no benefit and efficacy was poor in relapsing disease.

  • Smits, B.
  • Goldacker, S.
  • Seneviratne, S.
  • Malphettes, M.
  • Longhurst, H.
  • Mohamed, O. E.
  • Witt-Rautenberg, C.
  • Leeman, L.
  • Schwaneck, E.
  • Raymond, I.
  • Meghit, K.
  • Uhlmann, A.
  • Winterhalter, C.
  • van Montfrans, J.
  • Klima, M.
  • Workman, S.
  • Fieschi, C.
  • Lorenza, L.
  • Boyle, S.
  • Onyango-Odera, S.
  • Price, S.
  • Schmalzing, M.
  • Aurillac, V.
  • Prasse, A.
  • Hartmann, I.
  • Meerburg, J. J.
  • Kemner-van de Corput, M.
  • Tiddens, H.
  • Grimbacher, B.
  • Kelleher, P.
  • Patel, S. Y.
  • Korganow, A. S.
  • Viallard, J. F.
  • Tony, H. P.
  • Bethune, C.
  • Schulze-Koops, H.
  • Witte, T.
  • Huissoon, A.
  • Baxendale, H.
  • Grigoriadou, S.
  • Oksenhendler, E.
  • Burns, S. O.
  • Warnatz, K.

Keywords

  • Cvid
  • Granulomatous and lymphocytic interstitial lung disease
  • Hartmann Score
  • corticosteroids
  • gl-ILD
  • immune dysregulation
  • observational trial
  • pulmonary function tests
  • quality of life
Publication details
DOI: 10.1016/j.jaci.2022.12.813
Journal: J Allergy Clin Immunol
Work Type: Original
Location: BREATH
Disease Area: DPLD
Partner / Member: MHH
Access-Number: 36587851

DZL Engagements

chevron-down